Literature DB >> 29402806

Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival.

Zhen Yang1, WeiHua Wang1,2, JingFeng Lu1,2, Gaofeng Pan1, Zhiyu Pan1, Qian Chen1, Weiyan Liu1, Yanping Zhao1,3.   

Abstract

BACKGROUND/AIMS: Gastric neuroendocrine tumors (G-NETs) are uncommon neoplasms that can present with or without clinical symptoms. In this study, we evaluated the incidence, prognosis, and temporal trends of G-NETs.
METHODS: We analyzed all cases of G-NETs registered in the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2014. Incidence was estimated by age and joinpoint analyses. Survival rates were calculated and survival trends over time were evaluated.
RESULTS: A total of 3740 eligible patients were enrolled in the study. G-NETs incidence increased from 0.31 per 1 000 000 patients in 1975 to 4.85 in 2014, with an annual percentage changes (APCs) of 8.9% (95% confidence interval [CI] = 7.7% to 10.21%, P < 0.001, t test (29) from 1975 to 2001 and 3.6% from 2002 to 2014 (95% CI= 2.3% to 4.9%, P < 0.001). For cases diagnosed between 1973 and 1982, five-year survival was 62.8% ± 7.0% (Standard error, SE) and increased to 86.7% ± 0.7% for cases diagnosed between 2003 and 2012 (P < 0.001). Years of diagnosis, gender, age at diagnosis, marital status, grade, tumor size, tumor stage, and surgery performed or not were the strongest predictors of worse survival in both univariate and multivariate analysis (P<0.05).
CONCLUSION: G-NETs are uncommon neoplasms but the incidence is growing. Survival has improved in the past decades. Years of diagnosis, gender, age at diagnosis, marital status, grade, tumor size, tumor stage, and surgery status predict survival in patients with G-NETs.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Gastric neuroendocrine tumors; Incidence; Survival status

Mesh:

Year:  2018        PMID: 29402806     DOI: 10.1159/000486915

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  13 in total

1.  Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience.

Authors:  Yusuf Karakaş; Şahin Laçin; Olcay Kurtulan; Ece Esin; Veli Sunar; Cenk Sökmensüer; Saadettin Kılıçkap; Şuayib Yalçin
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

2.  Value of computed tomography evaluation in pathologic classification and prognosis prediction of gastric neuroendocrine tumors.

Authors:  Shida Yan; Tongtong Liu; Ying Li; Yongjian Zhu; Jun Jiang; Liming Jiang; Hong Zhao
Journal:  Ann Transl Med       Date:  2019-10

3.  Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research.

Authors:  Ping Hu; Jian'an Bai; Min Liu; Jingwen Xue; Tiaotiao Chen; Rui Li; Xiaoling Kuai; Haijian Zhao; Xiaolin Li; Ye Tian; Wei Sun; Yujia Xiong; Qiyun Tang
Journal:  Gastric Cancer       Date:  2020-02-05       Impact factor: 7.370

4.  Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: A population-based study.

Authors:  Fang-Xi Tian; Yu-Qing Cai; Lv-Ping Zhuang; Ming-Fang Chen; Zhong-Biao Xiu; Yi Zhang; Hong Liu; Zhi-Hong Liu; Guo-Ping Liu; Chen Zeng; Fei-Ling Lin; Jing Liu; Si-Ting Huang; Liang-Zhi Zhang; Hua-Yang Lin
Journal:  Cancer Med       Date:  2018-10-11       Impact factor: 4.452

5.  Gastric neuroendocrine neoplasias: manifestations and comparative outcomes.

Authors:  S Felder; H Jann; R Arsenic; T Denecke; V Prasad; B Knappe-Drzikova; S Maasberg; B Wiedenmann; M Pavel; A Pascher; U F Pape
Journal:  Endocr Relat Cancer       Date:  2019-09       Impact factor: 5.678

6.  A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors.

Authors:  Yingying Chen; Deng Han; Jiqing Zhu; Jie Chen; Haiyi Hu; Dou Dou; Xin Wang; Bing Yuan; Chao Wang; Zhirong Qi; Xinran Zhang; Jixi Liu; Jie Luo; Huangying Tan
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

7.  Gastric Carcinoid: The Invisible Tumor!

Authors:  Samyak Dhruv; Shamsuddin Anwar; Abhishek Polavarapu; Deeb Liliane
Journal:  Cureus       Date:  2021-02-25

8.  Changing Disparity of Gastric Cancer Incidence by Histological Types in US Race-Specific Populations.

Authors:  Xuan Zhu; Alessio Pigazzi; Jason Zell; Yunxia Lu
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

Review 9.  What is New in the 2019 World Health Organization (WHO) Classification of Tumors of the Digestive System: Review of Selected Updates on Neuroendocrine Neoplasms, Appendiceal Tumors, and Molecular Testing.

Authors:  Naziheh Assarzadegan; Elizabeth Montgomery
Journal:  Arch Pathol Lab Med       Date:  2021-06-01       Impact factor: 5.686

Review 10.  New Developments in Gastric Neuroendocrine Neoplasms.

Authors:  Klaire Exarchou; Nathan A Stephens; Andrew R Moore; Nathan R Howes; D Mark Pritchard
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.